Get the app
US › Healthcare

TuHURA Biosciences Inc (HURA)

US · Healthcare · Biotechnology

$1.76-3.83%
Last close · 2026-10-16

Latest quarter · ended 2026-06-30

Revenue
$0
Net profit
$-9.2M
EPS
$-0.14
EPS estimate
$-0.15

EPS came in at -0.14 against a street estimate of -0.15 — a beat of 6.7%.

Key statistics

Market cap
$115.3M
Forward P/E
0.0
P/B
7.17
Book value
$0.29
EPS (TTM)
$-0.52
52-week high
$3.43
52-week low
$0.41
50-day MA
$2.10
200-day MA
$1.89

Analyst view

Analysts rate TuHURA Biosciences Inc a strong buy (4 buy, 0 hold, 0 sell out of 4) with an average price target of $8.04.

Shareholding

Insiders
34.62%
Institutions
14.19%

Largest institutional holders

FundStake
Vanguard Capital Management, LLC3.56%
Northern Trust Corp2.54%
BlackRock Inc1.08%
Geode Capital Management, LLC0.76%
Millennium Management LLC0.71%
AQR Capital Management LLC0.67%
Vanguard Fiduciary Trust Co0.39%
Citadel Advisors Llc0.36%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for TuHURA Biosciences Inc — free to start.

Open in the appGoogle PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncAmgen IncGilead Sciences IncAbbott LaboratoriesNovo Nordisk A/S

Data updated 2026-10-19.